The FDA approved a new dosing regimen for Lilly’s Alzheimer’s drug Kisunla intended to reduce the risk of side effects and make the drug…
New drugs designed to slow the progression of Alzheimer’s in the early stages, like Leqembi and Kisunla, might perform well in a carefully controlled…
Decades ago, University of Manchester biophysicist Ruth Itzhaki made a startling discovery: Her team found the cold sore-causing virus, herpes (HSV-1) in the brains…
This controversial, first-of-its-kind, algae-based drug for Alzheimer’s was approved in China. But citing financial concerns, the drugmaker is retiring it for good. Green Valley…
Despite approval from the UK health authority, the UK’s state-run insurer won’t pay for Alzheimer’s drugs Leqembi and Kisunla. The decision is not yet…
Since their discovery in the 1960s, stem cells have captivated our curiosity. Unlike other cells in the body, stem cells are changeable — they…
Is the fountain of youth really filled with Red Bull? Yes, according to some news headlines. “Common energy drink ingredient taurine ‘may slow aging…
Should healthy people take an Alzheimer’s blood test? Clinical guidelines say no. But Quest Diagnostics, one of America’s largest medical diagnostic companies, seemed to…
When people experience concerning memory problems — losing their keys more often, forgetting important events, or struggling to find the right word in the…
Researchers in China taught village health providers how to prescribe blood pressure medication. Despite not being doctors, this intervention lowered blood pressure and dementia…
After being rejected by EU regulators but approved in the U.S., UK, and several Middle Eastern countries, Alzheimer’s drug Kisunla added a new market:…
Everyone with Alzheimer’s disease has beta-amyloid plaques and tau tangles in their brain. But despite advances across blood tests, cerebrospinal fluid tests, and brain…
This installment of our quarterly Trials Update captures the latest developments in Alzheimer’s and other dementia clinical trials, from January 2025 to present. We’ve…
Fujirebio’s new blood test for Alzheimer’s biomarkers is the first to receive FDA approval, opening the door to Medicare coverage. Here’s what it can…
Common viral infections may make the brain more susceptible to dementia and other neurological diseases. For instance, the Epstein-Barr virus — which causes mononucleosis…